Histological and Memory Alterations in an Innovative Alzheimer's Disease Animal Model by Vanadium Pentoxide Inhalation

J Alzheimers Dis. 2024;99(1):121-143. doi: 10.3233/JAD-230818.

Abstract

Background: Previous work from our group has shown that chronic exposure to Vanadium pentoxide (V2O5) causes cytoskeletal alterations suggesting that V2O5 can interact with cytoskeletal proteins through polymerization and tyrosine phosphatases inhibition, causing Alzheimer's disease (AD)-like hippocampal cell death.

Objective: This work aims to characterize an innovative AD experimental model through chronic V2O5 inhalation, analyzing the spatial memory alterations and the presence of neurofibrillary tangles (NFTs), amyloid-β (Aβ) senile plaques, cerebral amyloid angiopathy, and dendritic spine loss in AD-related brain structures.

Methods: 20 male Wistar rats were divided into control (deionized water) and experimental (0.02 M V2O5 1 h, 3/week for 6 months) groups (n = 10). The T-maze test was used to assess spatial memory once a month. After 6 months, histological alterations of the frontal and entorhinal cortices, CA1, subiculum, and amygdala were analyzed by performing Congo red, Bielschowsky, and Golgi impregnation.

Results: Cognitive results in the T-maze showed memory impairment from the third month of V2O5 inhalation. We also noted NFTs, Aβ plaque accumulation in the vascular endothelium and pyramidal neurons, dendritic spine, and neuronal loss in all the analyzed structures, CA1 being the most affected.

Conclusions: This model characterizes neurodegenerative changes specific to AD. Our model is compatible with Braak AD stage IV, which represents a moment where it is feasible to propose therapies that have a positive impact on stopping neuronal damage.

Keywords: Alzheimer’s disease experimental model; Aβ plaques; Vanadium pentoxide; cell death; dendritic spine loss; inhaled exposure; neurofibrillary tangles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Alzheimer Disease* / chemically induced
  • Alzheimer Disease* / pathology
  • Amygdala / drug effects
  • Amygdala / pathology
  • Animals
  • Brain* / drug effects
  • Brain* / pathology
  • CA1 Region, Hippocampal / drug effects
  • CA1 Region, Hippocampal / pathology
  • Cerebral Amyloid Angiopathy / chemically induced
  • Cerebral Amyloid Angiopathy / pathology
  • Dendritic Spines / drug effects
  • Dendritic Spines / pathology
  • Disease Models, Animal*
  • Entorhinal Cortex / drug effects
  • Entorhinal Cortex / pathology
  • Frontal Lobe / drug effects
  • Frontal Lobe / pathology
  • Male
  • Maze Learning / drug effects
  • Neurofibrillary Tangles / drug effects
  • Neurofibrillary Tangles / pathology
  • Plaque, Amyloid / chemically induced
  • Plaque, Amyloid / pathology
  • Rats, Wistar
  • Spatial Memory* / drug effects
  • Vanadium Compounds* / administration & dosage
  • Vanadium Compounds* / toxicity

Substances

  • Vanadium Compounds
  • vanadium pentoxide